Addressing Palliative Sedation during Expert Consultation: A Descriptive Analysis of the Practice of Dutch Palliative Care Consultation Teams

Patrick Hoek1 *, Ilse Grandjean2, Constans A. H. H. V. M. Verhagen1, Marlies L. E. A. Jansen-Landheer2, Henk J. Schers3, Cilia Galesloot1, Kris C. P. Vissers1, Yvonne Engels1, Jeroen G.J. Hasselaar1

1 Department of Anesthesiology, Pain and Palliative Medicine, Radboud University Medical Center, Nijmegen, the Netherlands, 2 Comprehensive Cancer Centre the Netherlands, Utrecht, the Netherlands, 3 Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, the Netherlands

* Patrick.Hoek@Radboudumc.nl

Abstract

Main Objective

Since palliative sedation is considered a complex intervention, consultation teams are increasingly established to support general practice. This study aims to offer insight into the frequency and characteristics of expert consultations regarding palliative sedation.

Methods

We performed a retrospective analysis of a longitudinal database. This database contained all patient-related consultations by Dutch Palliative Care Consultation teams, that were requested between 2004 and 2011. We described the frequency and characteristics of these consultations, in particular of the subgroup of consultations in which palliative sedation was addressed (i.e. PSa consultations). We used multivariate regression analysis to explore consultation characteristics associated with a higher likelihood of PSa consultations.

Main Results and Their Significance

Of the 44,443 initial consultations, most were requested by general practitioners (73%) and most concerned patients with cancer (86%). Palliative sedation was addressed in 18.1% of all consultations. Palliative sedation was relatively more often discussed during consultations for patients with a neurologic disease (OR 1.79; 95% CI: 1.51–2.12) or COPD (OR 1.39; 95% CI: 1.15–1.69) than for patients with cancer. We observed a higher likelihood of PSa consultations if the following topics were also addressed during consultation: dyspnoea (OR 1.30; 95% CI: 1.22–1.40), agitation/delirium (OR 1.57; 95% CI: 1.47–1.68),
exhaustion (OR 2.89; 95% CI: 2.61–3.20), euthanasia-related questions (OR 2.65; 95% CI: 2.37–2.96) or existential issues (OR 1.55; 95% CI: 1.31–1.83).

Conclusion
In conclusion, PSa consultations accounted for almost one-fifth of all expert consultations and were associated with several case-related characteristics. These characteristics may help clinicians in identifying patients at risk for a more complex disease trajectory at the end of life.

Introduction
Palliative sedation (PS) is commonly applied in end-of-life care, but its frequency and characteristics vary between care settings and countries.[1–8] Palliative sedation involves the deliberate lowering of consciousness in patients nearing death to relieve the burden of refractory symptoms.[9] Refractory symptoms are “symptoms for which all possible treatment has failed, or it is estimated that no methods are available for palliation within the time frame and the risk-benefit ratio that the patient can tolerate”,[10] Because of the far-reaching consequences of palliative sedation, it is considered a treatment option of last resort.[11]

To guide medical practice concerning palliative sedation, several guidelines and frameworks have been published. Expert consultation is one of the topics addressed in these guidelines. For example, the Dutch national guideline on palliative sedation advises consultation with an “appropriate expert” when the attending physician lacks sufficient expertise and experience in the field of palliative sedation.[12] Expert consultation in the context of palliative sedation is also advocated by other frameworks and guidelines on palliative sedation, and some recommend mandatory consultation.[13–19]

Previous research conducted in the Netherlands shows that guideline recommendations on palliative sedation were increasingly applied in daily practice by Dutch physicians.[20] However, in the Netherlands, as well as in other countries, shortcomings were reported regarding the intention to use palliative sedation, the adequate usage of medication and communication with patients, informal caregivers and mutually between formal caregivers.[19–23] Furthermore, Swart et al. demonstrated that 41% of physicians believed that administering palliative sedation had a life-shortening effect and that 14% had experienced pressure to commence sedation, mainly from patients and their relatives.[24] Finally, it has been argued that individual general practitioners typically have little experience with palliative sedation in their caseload.[12,25] Altogether, these findings suggest that there is a substantial need for expert support concerning palliative sedation.

However, if expert consultation services are available, they seem to be used by health care professionals in only a minority of palliative sedation cases.[26–29] Koper et al. investigated considerations of Dutch physicians regarding expert consultations about palliative sedation. Main reasons for physicians to consult specialist palliative care services for palliative sedation are a lack of expertise and that consultation is considered supportive. Reasons not to use these consultation services were as follows: physicians having sufficient expertise themselves; consideration of palliative sedation as a normal medical procedure; time pressure; fear of disagreement with the consultant; and considering consultation as having little added value.[30] An alternative approach to gain additional insight in consultation practices concerning palliative sedation...
sedation is to study, nationwide, the documentation of requested consultations at expert consultation services.

Therefore, the aims of this study are to investigate the following over a period of 8 years: 1) the frequency and characteristics of palliative care consultations given by Dutch Palliative Care Consultation (PCC) teams, 2) the frequency and characteristics of consultations in which PS was addressed, and 3) the consultation characteristics associated with a higher likelihood of PS being addressed during consultation. These characteristic might help clinicians in identifying patients at risk for a more complex disease trajectory at the end of life, for whom timely consultation with an expert might be appropriate.

**Materials and Methods**

**Design**

We performed a retrospective analysis of a national database consisting of the registration of all consultations by Dutch PCC teams that were requested between 2004 and 2011.

**Setting**

In 1998, the Dutch government installed a national program for the development and improvement of palliative care. As a result of this program, regional PCC teams were established to ensure the availability of specific advice concerning palliative care for all professional caregivers. In 2011, 23 PCC teams were available for expert consultation, covering the whole country. PCC teams generally consist of general practitioners, medical specialists and specialized nurses who are recruited from regional health centers and hospitals. PCC team members are practicing healthcare professionals who have a special interest in palliative care and are trained in such. Some PCC teams offer a 24/7-consultation service, while others are available for consultation only during weekdays and to a limited extent during out-of-office hours. Most consultations were requested and answered by phone (approximately 90% in 2011).[31] Often, advice given by consultants is previously discussed with one or more fellow consultants.[31,32] Recommendations are mainly communicated by phone and, as much as possible, confirmed in writing. Only in a small minority of cases bedside consultations occur.[31] For each individual consultation, consultants themselves registered their specific clinical findings, diagnosis, treatment advice and other appointments in a national, standardized, web-based, consultation database (PRADO, IKNL, Ecommany, the Netherlands).

**Participants**

In PRADO, a number of characteristics were systematically recorded for every consultation, mainly using tick boxes: date of consultation, region of consultation, patient demographics (date of birth, age, gender), diagnosis, estimated prognosis, listed symptoms and problems, place of residence and the specialty or training of the professional caregiver requesting the consultation. With regard to the listed problems, within PRADO the following sentence is displayed: “the consultation concerns the following problems...”. Subsequently, the consultant lists one or more problems that have been addressed during consultation, using tick boxes. “Palliative sedation”, is one of the options available in this list.

We grouped consultations based on whether or not “palliative sedation” was selected by the consultant. As a result, two groups were defined: 1) consultations in which palliative sedation was addressed by the consulting caregiver and/or the consultant and registered as such in PRADO (PS addressed, abbreviated as PSa consultations), 2) other consultations (PS not
addressed, abbreviated as PSna consultations). To prevent duplication of cases, we included only the first consultation for every patient.

Statistical analysis and main outcome measures
Data were exported from the PRADO system into a Comma-Separated Value (CSV) file. Data were anonymized and de-identified and were subsequently imported and analyzed in Stata, Version 12.0 (StataCorp. 2011. *Stata Statistical Software: Release 12*. StataCorp LP, College Station, Texas, United States).

The number of annual consultations for PCC teams was described and displayed as a percentage of the annual mortality rates as registered by Statistics Netherlands (CBS). Proportions and 95% confidence intervals (95% CIs) were used to describe differences in characteristics between PSa consultations and PSna consultations. Differences in characteristics were analyzed for statistical significance using uni- and multivariate regression analysis. A p-level < 0.05 was considered statistically significant.

Ethical considerations
The Committee on Research Involving Human Subjects (CMO) Region Arnhem-Nijmegen stated that no further ethical assessment was required for this research. (Reg. 2013/423). Informed consent was not obtained, since we only used data from an existing, clinical database, that was anonymized and de-identified prior to analysis.

Results
General description of all palliative care consultations
During the study period, 44,443 first consultations were registered and included for analysis. The vast majority of these consultations were requested by general practitioners (GPs) (72.7%) and concerned patients residing at home (74.7%). Most patients enlisted for consultation were diagnosed with cancer (86.1%). The most frequently listed symptoms were pain (45.0%), agitation/delirium (15.4%), dyspnoea (15.4%), and nausea/vomiting (15.0%). Other topics frequently addressed during consultation related to pharmacological questions (51.2%), moral support for the professional caregivers themselves (33.7%) and issues about the organization of care (23.7%). More than half of the consultations (56.8%) concerned patients with an estimated prognosis of less than 4 weeks. The vast majority of consultations were requested during office hours (85.0%) (Table 1). The annual consultation rate, in relation to the annual mortality number, rose during the first years of the study, from 3.6% (95% CI: 3.5%-3.7%) in 2004 to 4.8% (95% CI: 4.7%-4.9%) in 2006. After 2006, annual consultation rates declined until 2008 and remained rather stable at approximately 4% afterwards (Table 2).

PSa consultations
Palliative sedation was addressed in 8,038 (18.1%) of the consultations. PSa consultations were most often requested by GPs (87.4% of all PSa consultations, 7,023 PSa consultations) and most often concerned patients diagnosed with cancer (82.1%, 6,597 PSa consultations). Since 86.1% (38,248 consultations) of all consultations concerned patients diagnosed with cancer, the proportion of PSa consultations for this group of patients was relatively low (17.2%; 95% CI: 16.9%-17.6%). Relatively high proportions of PSa consultations were found for patients diagnosed with heart failure (25.0%; 95% CI: 22.5%-27.5%), neurologic diseases (22.9%; 95% CI: 20.4%-25.4%), chronic obstructive pulmonary disease (COPD) (26.4%; 95% CI: 23.1%-29.6%), and other diagnoses (23.8%; 95% CI: 22.1%-25.5%). Furthermore, palliative sedation
Table 1. Characteristics of all consultations by Dutch PCC teams (2004–2011).

| Variable                        | All consultations | PSa consultations | Proportion of PSa consultations* |
|---------------------------------|-------------------|-------------------|----------------------------------|
|                                 | n     | %     | n     | %     | % (95% CI) |
| **Year of consultation**        |       |       |       |       |            |
| 2004                            | 4,851 | 10.9  | 509   | 6.3   | 10.5 (9.6–11.4) |
| 2005                            | 5,508 | 12.4  | 735   | 9.1   | 13.3 (12.4–14.2) |
| 2006                            | 6,465 | 14.6  | 1,178 | 14.6  | 18.2 (17.3–19.2) |
| 2007                            | 6,044 | 13.6  | 1,145 | 14.2  | 18.9 (18.0–19.9) |
| 2008                            | 5,283 | 11.9  | 1,127 | 14.0  | 21.3 (20.2–22.4) |
| 2009                            | 5,532 | 12.5  | 1,111 | 13.8  | 20.1 (19.0–21.1) |
| 2010                            | 5,638 | 12.7  | 1,125 | 14.0  | 20.0 (18.9–21.0) |
| 2011                            | 5,122 | 11.5  | 1,108 | 13.8  | 21.6 (20.5–22.8) |
| **Consultation region**         |       |       |       |       |            |
| North                           | 5,728 | 12.9  | 924   | 11.5  | 16.1 (15.2–17.1) |
| East                            | 11,536| 26.0  | 1,577 | 19.6  | 13.7 (13.0–14.3) |
| South                           | 8,591 | 19.3  | 1,460 | 18.2  | 17.0 (16.2–17.8) |
| West                            | 10,760| 24.2  | 2,011 | 25.0  | 18.7 (18.0–19.4) |
| Middle                          | 7,828 | 17.6  | 2,066 | 25.7  | 26.4 (25.4–27.4) |
| **Consulting Professional Caregiver** |     |       |       |       |            |
| General practitioner            | 32,319| 72.7  | 7,023 | 87.4  | 21.7 (21.3–22.2) |
| Hospital specialist             | 2,666 | 6.0   | 196   | 2.4   | 7.4 (6.4–8.3) |
| Nurse                           | 5,183 | 11.7  | 331   | 4.1   | 6.4 (5.7–7.1) |
| Elderly care physician          | 1,674 | 3.8   | 244   | 3.0   | 14.6 (12.9–16.3) |
| Other                           | 2,586 | 5.8   | 242   | 3.0   | 9.4 (8.2–10.5) |
| Unknown                         | 15    | 0.03  | 2     | 0.02  | 13.3 (-3.9–30.5) |
| **Place of residence**          |       |       |       |       |            |
| Home                            | 33,190| 74.7  | 6,435 | 80.1  | 19.4 (19.0–19.8) |
| Hospice                         | 2,874 | 6.5   | 516   | 6.4   | 18.0 (16.6–19.4) |
| Nursing/Residential Home        | 3,328 | 7.5   | 683   | 8.5   | 20.5 (19.2–21.9) |
| Hospital                        | 4,008 | 9.0   | 271   | 3.4   | 6.8 (6.0–7.5) |
| Other                           | 928   | 2.1   | 121   | 1.5   | 13.0 (10.9–15.2) |
| Unknown                         | 115   | 0.3   | 12    | 0.2   | 10.4 (4.8–16.0) |
| **Gender**                      |       |       |       |       |            |
| Male                            | 22,593| 50.8  | 4,218 | 52.5  | 18.7 (18.2–19.2) |
| Female                          | 21,804| 49.1  | 3,813 | 47.4  | 17.5 (17.0–18.0) |
| Unknown                         | 46    | 0.1   | 7     | 0.1   | 15.2 (4.8–25.6) |
| **Age (years)**                 |       |       |       |       |            |
| 0–39                            | 1,473 | 3.3   | 258   | 3.2   | 17.5 (15.6–19.5) |
| 40–64                           | 16,189| 36.4  | 2,749 | 34.2  | 17.0 (16.4–17.6) |
| 65–79                           | 16,655| 37.5  | 2,947 | 36.7  | 17.7 (17.1–18.3) |
| ≥80                             | 9,435 | 21.2  | 1,969 | 24.5  | 20.9 (20.0–21.7) |
| Unknown                         | 691   | 1.6   | 115   | 1.4   | 16.6 (13.9–19.4) |
| **Diagnosis**                   |       |       |       |       |            |
| Cancer                          | 38,248| 86.1  | 6,597 | 82.1  | 17.2 (16.9–17.6) |
| Heart failure                   | 1,135 | 2.6   | 284   | 3.5   | 25.0 (22.5–27.5) |
| Neurologic disease              | 1,065 | 2.4   | 244   | 3.0   | 22.9 (20.4–25.4) |
| Chronic obstructive pulmonary disease (COPD) | 694 | 1.6 | 183 | 2.3 | 26.4 (23.1–29.6) |
| Other                           | 2,477 | 5.6   | 590   | 7.3   | 23.8 (22.1–25.5) |

(Continued)
was relatively often addressed in consultations in which the following symptoms or issues were also raised: exhaustion (proportion of PSa consultations: 28.7%; 95% CI: 27.1%-30.4%), agitation/delirium (28.2%; 95% CI: 27.2%-29.3%), dyspnoea (25.2%; 95% CI: 24.2%-26.2%), euthanasia-related (34.4%; 95% CI: 32.3%-36.5%), and existential issues (21.6%; 95% CI: 19.3%-24.0%). Also, a relatively high proportion of PSa consultations was found for patients with an estimated prognosis of less than 4 weeks (27.3%; 95% CI: 26.8%-27.9%). Finally, palliative sedation was addressed relatively often in consultations outside of office hours (23.5%; 95% CI: 22.4%-24.5%).

**Table 1. (Continued)**

| Variable                        | All consultations | PSa consultations | Proportion of PSa consultations* |
|---------------------------------|-------------------|-------------------|----------------------------------|
|                                 | n    | %    | n    | %    | % (95% CI) |
| Unknown                         | 824  | 1.9  | 140  | 1.7  | 17.0 (14.4–19.6) |
| **Symptoms**                    |       |      |       |      |            |
| Anorexia                        | 1,842 | 4.1  | 273  | 3.4  | 14.8 (13.2–16.4) |
| Dyspnoea                        | 6,858 | 15.4 | 1,728 | 21.5 | 25.2 (24.2–26.2) |
| Agitation/delirium              | 6,857 | 15.4 | 1,937 | 24.1 | 28.2 (27.2–29.3) |
| Decubitus/ulcus                 | 1,024 | 2.3  | 121  | 1.5  | 11.8 (9.8–13.8) |
| Depressed mood                  | 3,268 | 7.4  | 370  | 4.6  | 11.3 (10.2–12.4) |
| Nausea/vomiting                 | 6,680 | 15.0 | 899  | 11.2 | 13.5 (12.6–14.3) |
| Mouth problems                  | 1,149 | 2.6  | 156  | 1.9  | 13.6 (11.6–15.6) |
| Constipation/diarrhea           | 2,168 | 4.9  | 206  | 2.6  | 9.5 (8.3–10.7) |
| **Issues**                      |       |      |       |      |            |
| Pain                            | 19,977 | 45.0 | 2,924 | 36.4 | 14.6 (14.1–15.1) |
| Exhaustion                      | 2,981 | 6.7  | 857  | 10.7 | 28.7 (27.1–30.4) |
| Other                           | 8,412 | 18.9 | 1,463 | 18.2 | 17.4 (16.6–18.2) |
| **Estimated Prognosis**         |       |      |       |      |            |
| Less than 4 weeks               | 25,231 | 56.8 | 6,898 | 85.8 | 27.3 (26.8–27.9) |
| Between 4 weeks and 3 months    | 7,600  | 17.1 | 333  | 4.1  | 4.4 (3.9–4.8) |
| More than 3 months              | 3,394  | 7.6  | 82   | 1.0  | 2.4 (1.9–2.9) |
| Unknown                         | 8,218  | 18.5 | 725  | 9.0  | 8.8 (8.2–9.5) |
| **Time of consultation**        |       |      |       |      |            |
| Out-of-office hours             | 6,377  | 14.4 | 1,497 | 18.6 | 23.5 (22.4–24.5) |
| Office hours                    | 37,763 | 85.0 | 6,509 | 80.1 | 17.2 (16.9–17.6) |
| Unknown                         | 303    | 0.7  | 32   | 0.4  | 10.6 (7.1–14.0) |

**PCC teams:** Palliative Care Consultation Team; **PS:** palliative sedation; **PSa consultation:** palliative sedation addressed during consultation; 95% **CI:** 95% confidence interval.

* Proportion = (PSa consultations / total consultations)*100%, per single variable.

**b** Total of variables for “Symptoms” and “Issues” exceeds 100% due to more than one symptom / issue registered per consultation.

doi:10.1371/journal.pone.0136309.t001
Addressing Palliative Sedation during Consultations at Dutch PCC Teams

Table 2. Number of all consultations by Dutch PCC teams over the period 2004–2011.

| Year of consultation | AMN | All consultations | PSa consultations |
|----------------------|-----|-------------------|-------------------|
|                      | n   | n % of AMN (95% CI) | n % of AMN (95% CI) |
| 2004                 | 136,553 | 4,851 (3.5–3.7)      | 509 (0.3–0.4)     |
| 2005                 | 136,402 | 5,508 (3.9–4.1)      | 735 (0.5–0.6)     |
| 2006                 | 135,372 | 6,465 (4.7–4.9)      | 1,178 (0.8–0.9)   |
| 2007                 | 133,022 | 6,044 (4.4–4.7)      | 1,145 (0.9–0.9)   |
| 2008                 | 135,136 | 5,283 (3.8–4.0)      | 1,127 (0.8–0.9)   |
| 2009                 | 134,235 | 5,532 (4.0–4.2)      | 1,111 (0.8–0.9)   |
| 2010                 | 136,058 | 5,638 (4.0–4.3)      | 1,125 (0.8–0.9)   |
| 2011                 | 135,741 | 5,122 (3.7–3.9)      | 1,108 (0.8–0.9)   |

PCC teams: Palliative Care Consultation Teams; AMN: Annual Mortality Number; PS: palliative sedation; PSa consultation: palliative sedation addressed during consultation; 95% CI: 95% confidence interval.
doi:10.1371/journal.pone.0136309.t002

Over the years, palliative sedation was increasingly addressed during PCC consultations, from 10.5% of cases in 2004 (95% CI: 9.6%–11.4%) to 21.6% of cases in 2011 (95% CI: 20.5%–22.8%). PSa consultation rates as a percentage of annual mortality numbers varied between 0.4% in 2004 (95% CI: 0.3%–0.4%) to 0.9% in 2006 and 2007 (95% CI: 0.8%–0.9% for both years) (Table 2).

**Multivariate regression analysis—characteristics associated with PSa consultations**

The following characteristics were associated with a higher likelihood of palliative sedation being addressed during palliative care consultations: 1) patients being diagnosed with a neurologic disease (OR 1.79, 95% CI: 1.51–2.12) or COPD (OR 1.39, 95% CI: 1.15–1.69) compared to cancer (reference variable) and 2) the presence of dyspnoea (OR 1.30, 95% CI: 1.22–1.40), agitation/delirium (OR 1.57; 95% CI: 1.47–1.68), exhaustion (OR 2.89; 95% CI: 2.61–3.20), euthanasia-related issues (OR 2.65; 95% CI: 2.37–2.96) or existential issues (OR 1.55; 95% CI: 1.31–1.83). The following characteristics were associated with a lower likelihood of palliative sedation being addressed during consultations: 1) patients having a prognosis of more than 4 weeks ((OR 0.15 (95% CI: 0.13–0.16) for an estimated prognosis of “between 4 weeks and 3 months” and 0.08 (95% CI: 0.06–0.10) for “more than 3 months,” respectively), 2) professional caregivers other than the GP being the caregivers requesting consultation (OR varying from 0.36 for nurses (95% CI: 0.32–0.41) to 0.61 for elderly care physicians (95% CI: 0.51–0.72)) and 3) the timing of the consultation characterized as “during office hours” (OR 0.88; 95% CI: 0.82–0.95) compared to “out-of-office hours” (reference variable) (Table 3).

**Discussion**

**Main results**

Palliative sedation was addressed in approximately one out of five palliative care consultations in the Netherlands during the period 2004–2011. The likelihood of palliative sedation being addressed during consultations was higher if the consultations were requested by GPs and during "out of office" hours. Additionally, palliative sedation was relatively more often addressed for patients with a non-cancer diagnosis, for patients with an estimated prognosis of less than 4 weeks.
Table 3. Univariate and multivariate analysis of all consultations by Dutch PCC teams (2004–2011)—Characteristics associated with PSa consultations.

| Characteristics                        | Univariate analysis | Multivariate analysis |
|----------------------------------------|---------------------|-----------------------|
|                                        | Odds ratio (95% CI) | Odds ratio (95% CI)   |
| **Year of consultation**               |                     |                       |
| 2004                                   | 1 (reference)       | 1 (reference)         |
| 2005                                   | 1.31 (1.16–1.48)    | 1.41 (1.24–1.61)      |
| 2006                                   | 1.90 (1.70–2.12)    | 1.69 (1.49–1.91)      |
| 2007                                   | 1.99 (1.78–2.23)    | 1.66 (1.47–1.88)      |
| 2008                                   | 2.31 (2.07–2.59)    | 2.26 (1.99–2.57)      |
| 2009                                   | 2.14 (1.91–2.40)    | 2.11 (1.86–2.40)      |
| 2010                                   | 2.13 (1.90–2.38)    | 1.98 (1.74–2.24)      |
| 2011                                   | 2.35 (2.10–2.64)    | 2.17 (1.91–2.47)      |
| **Consultation region**                |                     |                       |
| North                                  | 1 (reference)       | 1 (reference)         |
| East                                   | 0.82 (0.75–0.90)    | 0.90 (0.81–0.99)      |
| South                                  | 1.06 (0.97–1.16)    | 1.28 (1.15–1.41)      |
| West                                   | 1.20 (1.09–1.30)    | 1.19 (1.08–1.31)      |
| Middle                                 | 1.86 (1.71–2.03)    | 1.42 (1.29–1.57)      |
| **Consulting professional caregiver**  |                     |                       |
| General practitioner                   | 1 (reference)       | 1 (reference)         |
| Hospital specialist                    | 0.29 (0.25–0.33)    | 0.52 (0.42–0.64)      |
| Nurse                                  | 0.25 (0.22–0.28)    | 0.36 (0.32–0.41)      |
| Elderly care physician                 | 0.61 (0.54–0.71)    | 0.61 (0.51–0.72)      |
| Other                                  | 0.37 (0.32–0.43)    | 0.52 (0.45–0.61)      |
| Unknown                                | 0.55 (0.13–2.46)    | 0.78 (0.17–3.70)      |
| **Place of residence**                |                     |                       |
| Home                                   | 1 (reference)       | 1 (reference)         |
| Hospice                                | 0.91 (0.82–1.00)    | 1.09 (0.97–1.22)      |
| Nursing/Residential home               | 1.07 (0.98–1.17)    | 1.02 (0.91–1.14)      |
| Hospital                               | 0.30 (0.27–0.34)    | 0.70 (0.59–0.84)      |
| Other                                  | 0.62 (0.51–0.76)    | 0.85 (0.69–1.05)      |
| Unknown                                | 0.48 (0.27–0.88)    | 0.83 (0.43–1.58)      |
| **Gender**                             |                     |                       |
| Male                                   | 1 (reference)       | 1 (reference)         |
| Female                                 | 0.92 (0.88–0.97)    | 0.98 (0.93–1.03)      |
| Unknown                                | 0.78 (0.35–1.75)    | 1.11 (0.44–2.78)      |
| **Age (years)**                        |                     |                       |
| 0–39                                   | 1 (reference)       | 1 (reference)         |
| 40–64                                  | 0.96 (0.84–1.11)    | 0.93 (0.80–1.09)      |
| 65–79                                  | 1.01 (0.88–1.16)    | 0.93 (0.79–1.08)      |
| ≥ 80                                   | 1.24 (1.07–1.43)    | 0.93 (0.80–1.10)      |
| Unknown                                | 0.94 (0.74–1.20)    | 1.09 (0.83–1.43)      |
| **Diagnosis**                          |                     |                       |
| Cancer                                 | 1 (reference)       | 1 (reference)         |
| Heart failure                          | 1.60 (1.40–1.84)    | 1.15 (0.98–1.34)      |
| Neurologic disease                     | 1.43 (1.23–1.65)    | 1.79 (1.51–2.12)      |
| Chronic obstructive pulmonary disease (COPD) | 1.72 (1.45–2.04)    | 1.39 (1.15–1.69)      |
| Other                                  | 1.50 (1.36–1.65)    | 1.53 (1.37–1.72)      |

(Continued)
weeks, and for patients with dyspnoea, agitation/delirium, exhaustion, euthanasia-related or existential issues.

### Strengths and weaknesses

A main strength of this study is the use of a national, standardized database containing all consultations for Dutch PCC teams in the Netherlands that were provided and registered in the period 2004 to 2011. By using this database, we were able to give a detailed overview of the practice of palliative care consultations during this period. The number of missing values is low (≤2% of all cases per variable) for most variables. However, Schrijnemakers et al. demonstrated

| **Table 3. (Continued)** |
|--------------------------|
|                          | **Univariate analysis** | **Multivariate analysis** |
|                          | **Odds ratio (95% CI)** | **Odds ratio (95% CI)** |
| **Unknown**              | 0.98 (0.82–1.18)        | 1.06 (0.87–1.31)        |
| **Symptoms (present)**   |                          |                          |
| Anorexia                 | 0.78 (0.68–0.89)        | 1.13 (0.97–1.32)        |
| Dyspnoea                 | 1.67 (1.57–1.77)        | 1.30 (1.22–1.40)        |
| Agitation/delirium       | 2.03 (1.91–2.16)        | 1.57 (1.47–1.68)        |
| Decubitus/ulcus          | 0.60 (0.50–0.73)        | 0.87 (0.70–1.08)        |
| Depressed mood           | 0.56 (0.50–0.62)        | 0.96 (0.84–1.09)        |
| Nausea/vomiting          | 0.67 (0.62–0.72)        | 0.72 (0.67–0.79)        |
| Mouth problems           | 0.71 (0.60–0.84)        | 0.92 (0.76–1.11)        |
| Constipation/diarrhea    | 0.46 (0.40–0.53)        | 0.66 (0.56–0.77)        |
| Pain                     | 0.65 (0.62–0.68)        | 0.74 (0.70–0.78)        |
| Exhaustion               | 1.93 (1.77–2.09)        | 2.89 (2.61–3.20)        |
| Other                    | 0.94 (0.89–1.00)        | 1.00 (0.93–1.08)        |
| **Issues (present)**     |                          |                          |
| Daily functioning        | 0.51 (0.46–0.56)        | 0.76 (0.69–0.85)        |
| Euthanasia-related       | 2.51 (2.28–2.76)        | 2.65 (2.37–2.96)        |
| Pharmacological          | 0.69 (0.66–0.73)        | 0.54 (0.51–0.58)        |
| Informal care            | 0.61 (0.55–0.68)        | 1.09 (0.97–1.24)        |
| Moral support professional caregiver | 0.80 (0.76–0.84) | 0.84 (0.79–0.90) |
| Organization of care     | 0.64 (0.60–0.68)        | 0.84 (0.78–0.90)        |
| Social                   | 0.46 (0.41–0.53)        | 0.87 (0.74–1.02)        |
| Existential              | 1.26 (1.09–1.45)        | 1.55 (1.31–1.83)        |
| Other                    | 0.40 (0.35–0.46)        | 0.46 (0.39–0.53)        |
| **Prognosis**            |                          |                          |
| Less than 4 weeks        | 1 (reference)           | 1 (reference)           |
| Between 4 weeks and 3 months | 0.12 (0.11–0.14)      | 0.15 (0.13–0.16)        |
| More than 3 months       | 0.07 (0.05–0.08)        | 0.08 (0.06–0.10)        |
| Unknown                  | 0.26 (0.24–0.28)        | 0.26 (0.24–0.28)        |
| **Time of consultation** |                          |                          |
| Out-of-office hours      | 1 (reference)           | 1 (reference)           |
| Office Hours             | 0.68 (0.64–0.72)        | 0.88 (0.82–0.95)        |
| Unknown                  | 0.38 (0.27–0.56)        | 1.02 (0.68–1.53)        |

**PCC teams**: Palliative Care Consultation Teams; **PS**: palliative sedation; **PSa consultation**: palliative sedation addressed during consultation; **95% CI**: 95% confidence interval.

doi:10.1371/journal.pone.0136309.t003
that during telephone consultation a substantial share of the present problems may not be discussed and subsequently not be registered.[32]

Furthermore, to prevent duplication of patients with multiple consultations in our study sample, we decided to include only the first consultation per patient. Consequently, follow-up consultations in which palliative sedation may have been addressed were not included. Nevertheless, our final sample included 89.3% of all PSa consultations (8,038 out of 9,005 PSa consultations) by Dutch PCC teams, which warrants the representativeness of our results. Another consequence of the study methods used is that we were not able to study which percentage of PSa consultations eventually led to the actual application of palliative sedation. Furthermore, palliative sedation was defined in a general way, therefore no distinction could be made between continuous and intermittent sedation. These factors hamper a comparison of our study to the international literature concerning the practice and incidence of palliative sedation. Also, since palliative sedation could only be registered by checking the tick-box “palliative sedation”, no additional information was available on this topic (e.g., who initiated discussion about palliative sedation?). Therefore PSa consultations may form a heterogeneous group of consultations.

Finally, consultation rates from this study must be interpreted with caution because we have studied only consultations delivered by PCC teams. Consequently, we did not take into account alternative sources for palliative care consultations (e.g., hospital specialists or colleagues specialized in palliative care). Rietjens et al. showed that physicians, particularly clinical specialists, but also 29% of the GPs, discuss sedation with other physicians rather than with a consultation service.[29] These “unofficial” consultations are not taken into account in our study. This may have led to an underestimation of consultation rates.

Comparison with the literature

We found an increase in PSa consultations over the period from 2004 to 2011. This appears to be in line with previous research describing the incidence of palliative sedation in the Netherlands and Belgium.[3,4,33] The sharpest increase can be observed between 2005 and 2006. This finding may be related to the publication of the guidelines on palliative sedation by the Royal Dutch Medical Association (RDMA) in 2005, most likely leading towards an increased awareness among practitioners.[20] In the Netherlands, the estimated incidence of (continuous) palliative sedation in 2010 was 12.3% of all deaths.[3] Similar or higher percentages were found in Belgium (14.5% in 2007) and the United Kingdom (18.7% in 2007/2008).[4,23,33] In our study, the PSa consultation rate (PSa consultations as a percentage of the annual number of deaths) in 2010 was 0.8%. This suggests one PSa consultation by PCC teams for every 15 cases of palliative sedation in the Netherlands (12.3%/0.8%). This rate is lower than the consultation rate of 22% found by Swart et al.[24] One explanation for this different consultation rate, could be that Swart et al. asked physicians whether they consulted any palliative care team, whereas we only studied consultations requested at PCC teams. Anyhow, our finding demonstrates that the use of PCC teams for palliative sedation seems not a common practice. This rate is probably higher for general practitioners, as PSa consultations in our study were mainly requested by general practitioners (87.4% of all PSa consultations), while, according to the literature, general practitioners only perform almost half of all sedations.[34]

Our study raised three further topics that warrant discussion. First, dyspnoea, agitation/delirium and exhaustion were significantly associated with a higher likelihood of palliative sedation being addressed during consultation compared to other listed symptoms. A systematic review by Maltoni et al. showed that the most common indication for palliative sedation is delirium (54%) followed by dyspnoea (30%).[35] The complex management of these
symptoms in end of life care is acknowledged in literature.\[36,37\] The finding that exhaustion is associated with a higher likelihood of PSa consultations is in line with other research conducted in the Netherlands, stating that exhaustion is a common indication to start palliative sedation.\[20,24\] However, it is not mentioned as a common indication for palliative sedation in recent international literature.\[35\] Furthermore, although pain is a commonly mentioned symptom during PSa consultations (2,924 PSa consultations; 36.4%), resonating with the literature,\[20,24,25\] it is not independently associated with a higher likelihood of PSa consultations. This might be a result of the overall high incidence of pain in all consultations requested at PCC teams (19,977 consultations; 45.0%). As a result of this high denominator, the proportion of PSa consultations is relatively low for pain.

Second, apart from symptoms, the underlying diagnosis appears relevant. Although cancer accounts for the vast majority of palliative care consultations,\[38\] palliative sedation was discussed relatively more often for patients diagnosed with COPD and neurologic diseases. This might be explained by the fact that patients with these diagnoses experience a relatively unpredictable disease trajectory.\[39,40\] On the one hand, this may result in an increased risk of a complex terminal trajectory with a higher chance at refractory symptoms and PSa consultation. On the other hand, this may result in uncertainty regarding the estimated prognosis of patients and the suitability of palliative sedation. It is therefore important that clinicians confronted with patients with an end-stage COPD or neurologic disease prepare advanced care planning for palliative care in time, including expert involvement.

Third, consultations in which existential issues were discussed were associated with a higher likelihood of palliative sedation being addressed during consultation. The RDMA guideline on palliative sedation recognizes that existential suffering may be among the refractory symptoms that lead to unbearable suffering and state that expert consultations for these problems are strongly recommended.\[12\] However, existential suffering as an indication for palliative sedation remains controversial.\[41\] Previous research has shown that euthanasia, rather than palliative sedation, is related to existential problems relatively often.\[42\] In this regard, it is also important to notice that addressing "euthanasia-related issues" and palliative sedation were highly interrelated in this study. PCC teams appear to have a role in supporting physicians to explore palliative care options for patient cases in which questions concerning euthanasia, existential issues and palliative sedation intermingle. Clinicians confronted with existential suffering in end-of-life care are therefore encouraged to seek support from expert teams to prevent palliative sedation being applied for controversial indications.

**Conclusion**

Expert consultation in the field of palliative sedation is advocated when physicians lack sufficient knowledge or expertise in the field of palliative sedation. However, mandatory consultation for palliative sedation, as argued by some, remains an ongoing debate in the recent literature.\[30,43\] From our study, the use of expert consultation services for palliative sedation does not appear to be a common practice. This might indicate a limited need for expert consultation as a result of physicians being sufficiently skilled in this area. It might also point to an already covered need for expert consultation provided by other healthcare professionals beyond regular consultation services. Finally, there might be a neglected need for expert consultations due to physicians being unaware of their limited expertise concerning palliative sedation. Further research is needed here.

Consultation rates for palliative sedation appear to be rather low. To verify the accuracy of these consultation rates, future research must reveal the use of expert consultation services other than established PCC teams. In addition, future research should yield more insight into
the needs of general practitioners concerning palliative sedation, which could guide current palliative care consultation teams in adapting their services to these needs. This might lead to an increase in consultation rates and eventually improve the practice of palliative sedation.

Supporting Information

S1 File. Additional information about the multivariate regression analysis. (XLSX)

Author Contributions

Conceived and designed the experiments: JH IG CG MJ. Analyzed the data: IG JH PH CV. Wrote the paper: PH JH IG CV MJ HS CG KV YE.

References

1. Miccinesi G, Rietjens JA, Deliens L, Paci E, Bosshard G, Nilstun T, et al. (2006) Continuous deep sedation: physicians' experiences in six European countries. J Pain Symptom Manage 31: 122–129. PMID: 16488345
2. Seymour J, Rietjens J, Bruinmsma S, Deliens L, Sterckx S, Mortier F, et al. (2014) Using continuous sedation until death for cancer patients: A qualitative interview study of physicians' and nurses' practice in three European countries. Palliat Med.
3. Onwuteaka-Philipsen BD, Brinkman-Stoppelenburg A, Penning C, de Jong-Kral GJ, van Delden JJ, van der Heide A (2012) Trends in end-of-life practices before and after the enactment of the euthanasia law in the Netherlands from 1990 to 2010: a repeated cross-sectional survey. Lancet 380: 908–915. doi: 10.1016/S0140-6736(12)61034-4 PMID: 22789501
4. Bilsen J, Cohen J, Chambaere K, Pousset G, Onwuteaka-Philipsen BD, Mortier F, et al. (2009) Medical end-of-life practices under the euthanasia law in Belgium. N Engl J Med 361: 1119–1121. doi: 10.1056/NEJM0904292 PMID: 19741238
5. Chiu TY, Hu WY, Lue BH, Cheng SY, Chen CY (2001) Sedation for refractory symptoms of terminal cancer patients in Taiwan. J Pain Symptom Manage 21: 467–472. PMID:11397604
6. Morita T (2004) Differences in physician-reported practice in palliative sedation therapy. Support Care Cancer 12: 584–592. PMID: 14991486
7. Kohara H, Ueoka H, Takeyama H, Murakami T, Morita T (2005) Sedation for terminally ill patients with cancer with uncontrollable physical distress. J Palliat Med 8: 20–25. PMID: 15662170
8. Fainsinger RL, Waller A, Bercovici M, Bengtson K, Landman W, Hosking M, et al. (2000) A multicentre international study of sedation for uncontrolled symptoms in terminally ill patients. Palliat Med 14: 257–265. PMID: 10974977
9. Morita T, Tsuneto S, Shima Y (2002) Definition of sedation for symptom relief: a systematic literature review and a proposal of operational criteria. J Pain Symptom Manage 24: 447–453. PMID: 12505214
10. de Graeff A, Dean M (2007) Palliative sedation therapy in the last weeks of life: a literature review and recommendations for standards. J Palliat Med 10: 67–85. PMID: 17298256
11. Lo B, Rubenfeld G (2005) Palliative sedation in dying patients: “we turn to it when everything else hasn’t worked”. JAMA 294: 1810–1816. PMID: 16219885
12. Royal Dutch Medical Association (2009) Guideline for Palliative Sedation. Utrecht, the Netherlands. Available: Accessed 16 December 2014.
13. Dean MM, Cellarius V, Henry B, Oneschuk D, Librach SL, Canadian Society Of Palliative Care Physicians Taskforce (2012) Framework for continuous palliative sedation therapy in Canada. J Palliat Med 15: 870–879. doi: 10.1089/jpm.2011.0498 PMID: 22747192
14. Morita T, Bito S, Kurihara Y, Uchitomi Y (2005) Development of a clinical guideline for palliative sedation therapy using the Delphi method. J Palliat Med 8: 716–729. PMID: 16128645
15. Kirk TW, Mahon MM, for the Palliative Sedation Task Force of the National Hospice and Palliative Care Organization Ethics Committee (2010) National Hospice and Palliative Care Organization (NHPCO) position statement and commentary on the use of palliative sedation in imminently dying terminally ill patients. J Pain Symptom Manage 39: 914–923. doi: 10.1016/j.jpainsymman.2010.01.009 PMID: 20471551
16. Report of the Council on Ethical and Judicial Affairs (2008) Sedation to Unconsciousness in End-of-Life Care. CEJA Report 5-A-08. Available: . Accessed 16 December 2014.

17. Cherny NI, Radbruch L, Board of the European Association for Palliative Care (2009) European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. Palliat Med 23: 581–593. doi: 10.1177/0269216309107024 PMID: 19858355

18. Broeckaert B, Mullie A, Gielen J, Desmet M, Declerck D, Vanden Bergh P, et al. (2012) Richtlijn palliatieve sedatie. Available: . [in Dutch]. Accessed 16 December 2014.

19. Cherny NI, on behalf of the ESMO Guidelines Working Group (2014) ESMO Clinical Practice Guidelines for Palliative Care. Available: . Accessed 16 December 2014.

20. Hasselaar JG, Verhagen SC, Wolff AP, Engels Y, Cruj BJ, Vissers KC (2009) Changed patterns in Dutch palliative sedation practices after the introduction of a national guideline. Arch Intern Med 169: 430–437. doi: 10.1001/archinternmed.2008.613 PMID: 19273772

21. Brinkkemper T, Klinkenberg M, Deliens L, Eliel M, Rietjens JA, Zuurmond WW, et al. (2011) Palliative sedation at home in the Netherlands: a nationwide survey among nurses. J Adv Nurs 67: 1719–1728. doi: 10.1111/j.1365-2648.2010.05614.x PMID: 21382079

22. Anquinet L, Rietjens JA, Van den Block L, Bossuyt N, Deliens L (2011) General practitioners’ report of continuous deep sedation until death for patients dying at home: a descriptive study from Belgium. Eur J Gen Pract 17: 5–13. doi: 10.3109/13814788.2010.536529 PMID: 21174517

23. Seale C (2010) Continuous deep sedation in medical practice: a descriptive study. J Pain Symptom Manage 39: 44–53. doi: 10.1016/j.jpainsymman.2009.06.007 PMID: 19854611

24. Swart S, van der Heide A, Brinkkemper T, van Zuylen L, Perez R, Rietjens J (2012) Continuous palliative sedation until death: practice after introduction of the Dutch national guideline. BMJ Supportive & Palliative Care.

25. Donker GA, Slotman FG, Spreeuwenberg P, Francke AL (2013) Palliative sedation in Dutch general practice from 2005 to 2011: a dynamic cohort study of trends and reasons. Br J Gen Pract 63: e669–e765. doi: 10.3399/bjgp13X673676 PMID: 24152481

26. Hasselaar JG, Reuzel RP, Verhagen SC, de Graeff A, Vissers KC, Cruj BJ (2007) Improving prescription in palliative sedation: compliance with Dutch guidelines. Arch Intern Med 167: 1166–1171. PMID: 17563025

27. Rietjens J, van Delden J, Onwuteaka-Philipsen B, Butting H, van der Maas P, van der Heide A (2008) Continuous deep sedation for patients nearing death in the Netherlands: descriptive study. BMJ 336: 810–813. doi: 10.1136/bmj.39504.531505.25 PMID: 18344245

28. Swart SJ, Rietjens JA, van Zuylen L, Zuurmond WW, Perez RS, van der Maas PJ, et al. (2012) Continuous palliative sedation for cancer and noncancer patients. J Pain Symptom Manage 43: 172–181. doi: 10.1016/j.jpainsymman.2011.04.004 PMID: 21925832

29. Rietjens JA, van der Heide A, Vrakking AM, Onwuteaka-Philipsen BD, Van der Wal G (2004) Physician reports of terminal sedation without hydration or nutrition for patients nearing death in the Netherlands. Ann Intern Med 141: 178–185. PMID: 15289214

30. Koper I, van der Heide A, Janssens R, Swart S, Perez R, Rietjens J (2014) Consultation with specialist palliative care services in palliative sedation: considerations of Dutch physicians. Support Care Cancer 22: 225–231. doi: 10.1007/s00520-013-1972-7 PMID: 24037413

31. Grandjean I, Galesloot C, Kinkenberg M (2012) Consultatie palliatieve zorg—Jaarverslag 2011. integraal kankercentrum Nederland (IKKNL). Available: . [in Dutch]. Accessed 16 December 2014.

32. Schrijnemaekers V, Courtens A, Kuin A, van der Linden B, Vernoij-Dassen M, van Zuylen L, et al. (2005) A comparison between telephone and bedside consultations given by palliative care consultation teams in the Netherlands: results from a two-year nationwide registration. J Pain Symptom Manage 29: 552–558. PMID: 15963863

33. Chambaere K, Bilsen J, Cohen J, Rietjens JA, Onwuteaka-Philipsen BD, Mortier F, et al. (2010) Continuous deep sedation until death in Belgium: a nationwide survey. Arch Intern Med 170: 490–493. doi: 10.1001/archinternmed.2009.542 PMID: 20212190

34. van der Heide A, Brinkman-Stoppeleburg A, van Delden H, Onwuteaka-Philipsen B (2012) euthanasie en andere medische beslissingen rond het levenseinde. ZonMW, The Hague, the Netherlands.

35. Maltoni M, Scarpi E, Rosati M, Derni S, Fabbri L, Martini F, et al. (2012) Palliative sedation in end-of-life care and survival: a systematic review. J Clin Oncol 30: 1378–1383. doi: 10.1200/JCO.2011.37.3795 PMID: 22412129

36. Bush SH, Leonard MM, Agar M, Spiller JA, Hosie A, Wright DK, et al. (2014) End-of-life delirium: issues regarding recognition, optimal management, and the role of sedation in the dying phase. J Pain Symptom Manage 48: 215–230. doi: 10.1016/j.jpainsymman.2014.05.009 PMID: 24879997
37. Tsai JS, Wu CH, Chiu TY, Hu WY, Chen CY (2006) Symptom patterns of advanced cancer patients in a palliative care unit. Palliat Med 20: 617–622. PMID: 17060255

38. Potter J, Hami F, Bryan T, Quigley C (2003) Symptoms in 400 patients referred to palliative care services: prevalence and patterns. Palliat Med 17: 310–314. PMID: 12822846

39. Murray SA, Kendall M, Boyd K, Sheikh A (2005) Illness trajectories and palliative care. BMJ 330: 1007–1011. PMID: 15860828

40. Beernaert K, Cohen J, Deliens L, Devroey D, Vanthomme K, Pardon K, et al. (2013) Referral to palliative care in COPD and other chronic diseases: a population-based study. Respir Med 107: 1731–1739. doi: 10.1016/j.rmed.2013.06.003 PMID: 23810150

41. Papavasiliou EE, Payne S, Brearley S, on behalf of EUROIMPACT (2014) Current debates on end-of-life sedation: an international expert elicitation study. Support Care Cancer.

42. Rietjens JA, van Delden JJ, van der Heide A, Vrakking AM, Onwuteaka-Philipsen BD, van der Maas PJ, et al. (2006) Terminal sedation and euthanasia: a comparison of clinical practices. Arch Intern Med 166: 749–753. PMID: 1660811

43. Robijn L, Raus K, Deliens L, Sterckx S, Chambaere K (2014) Mandatory consultation for palliative sedation? Reflections on Koper et al. Support Care Cancer.